search
Back to results

Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children

Primary Purpose

Bone Fractures

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Ketamine and saline
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bone Fractures

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients 5-17 years (up to 80 kg) presenting to the paediatric ED who require a PCS for an acute simple orthopedic injuries who require a procedural sedation and analgesia (PSA). A "simple" injury is defined as a fracture or dislocation that: 1) Angulated with or without displacement but is not shortened) 2) Non-comminuted

Exclusion Criteria:

  • 1) Previous hypersensitivity reaction to ketamine including rash, difficulty breathing, hypotension, apnea, or laryngospasm 2) Globe rupture 3) Traumatic brain injury with intracranial hemorrhage 4) History of uncontrolled hypertension 5) Nasal bone deformity 6) Fracture reduction expected to require > 20 minutes 7) Poor English fluency 8) American Society of Anesthesiologists (ASA) class of 3 or greater 9) Previous sedation with ketamine within 24 hours of index visit 10) Known diagnosis of schizophrenia or active psychosis 11) Pregnancy

Sites / Locations

  • Children's Hospital, London Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intranasal ketamine and saline

Intravenous ketamine and saline

Arm Description

Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg

Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares

Outcomes

Primary Outcome Measures

University of Michigan Sedation Score
The primary outcome is the UMSS score at 10 minutes post administration of the IV intervention compared to UMSS score immediately prior to the first IN intervention (delta) using the University of Michigan Sedation Scale (UMSS)

Secondary Outcome Measures

Onset of sedation
Time interval from first IN spray to UMSS score of greater than 3 in minutes
Duration of sedation
Time interval from UMSS score greater than 3 to a UMSS score of 0 in minutes
Adverse events
Obtained when patient fully awake and prior to discharge from the participant, physician report and corroborated with nursing sedation record
Length of stay
Time from arrival in ED bed to discharge in minutes
Length of stay due to sedation
Time from first IN spray to discharge in minutes
Duration of procedure
Time from first IN spray to end of cast application
Parental satisfaction
Obtained immediately prior to discharge using a 5-item Likert scale; Parents not wishing to remain in proximity of child for sedation may opt out
Child satisfaction
Obtained immediately prior to discharge using a 5-item Likert scale
Sedating physician satisfaction
Obtained immediately prior to discharge using a 5-item Likert scale
Adjunctive sedative medication
Number of doses and type of adjunctive sedative medication required
Analgesic medication
Number of doses and type of analgesic medication required
Pain
Child's self reported pain score using the Faces Pain Scale - Revised
Emergence Agitation
Degree of emergency agitation and delirium as recorded by observer using the Paediatric Anesthesia Emergency Delirium (PAED) scale
Nasal Irritation
Recorded using a 5-item Likert scale anchored from 1=none to 5=very severe when child has a UMSS score of 0 and is awake and drinking
Successful sedation
Successful sedation - Based on the definition of Bhatt et al., this will be defined as no unpleasant patient recall of the procedure, no resistance or restraint required during the procedure, no permanent sedation-related complication or no sedation-related event requiring abandonment of the procedure. Defined as: no unpleasant patient recall of the procedure, no resistance or restraint required during the procedure, no permanent sedation-related complication or no sedation-related event requiring abandonment of the procedure. Defined as no unpleasant recall of procedure, no resistance or restraint, no permanent sedation related complication, no sedation-related event requiring abandonment of procedure

Full Information

First Posted
March 25, 2015
Last Updated
August 11, 2018
Sponsor
Lawson Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02402868
Brief Title
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children
Official Title
Intranasal Ketamine Versus Intravenous Ketamine for Procedural Conscious Sedation in Children: a Multi-centre Randomized Controlled Non-inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
January 2016 (undefined)
Primary Completion Date
January 2018 (Actual)
Study Completion Date
February 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lawson Health Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will examine the effectiveness of intranasal (IN) ketamine compared to standard intravenous (IV) ketamine administration for simple reductions of orthopaedic injuries in the paediatric population. The aim is to assess if IN administration is equivalent to the current standard of care, IV. The population to be studied is children 5-17 years of age who require a simple orthopaedic reduction. Following a double dummy approach to overcome the difficulty in masking interventions, each participant will recieve both IV and IN interventions, only one of which will be the real drug. Procedural conscious sedation (PCS) will be assessed using the University of Michigan Sedation Scale (UMSS).
Detailed Description
Randomization and concealment of allocation will be pharmacy-controlled using a computer-based random number generator. The treating physician, research assistant, and participant will be blinded to the intervention. Eligible participants will be randomized in a 1:1 allocation ratio with a stratified block design of six to either (1) IN ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 1.5 mL) PLUS IV 0.9% NS 0.02 mL/kg or (2) IV ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares. Due to the perceptible differences in interventional routes, each participant will receive both IV and IN interventions using this double-dummy approach. For IN dose volumes less than or equal to 0.5 mL, the entire dose will be delivered into 1 nostril and for doses greater than 0.5 mL, the dose will be divided equally between both nares. Adjuctive sedation will be given as needed in the form of IV ketamine, 1 mg/kg every 10 minutes for participants who do not achieve adequate sedation at 20 minutes (UMSS score of 4). A figure of the atomizer device used to deliver the IN agent has been uploaded. Eligible participants (defined in section 2.5 above) will be identified by the treating physician after viewing the radiographs and performing a clinical assessment. The physician will then inform a research assistant (RA) that the participant is eligible. The RA will then seek informed consent and explain the protocol to the family. Baseline demographic information will be obtained. Informed consent for PCS and a pre-anesthetic assessment will be performed by the treating physician in accordance with the usual standard of care. UMSS scores will be obtained by a trained RA at 5 minutes pre-intervention, intervention (0 minutes) and every 5 minutes thereafter for 60 minutes post-intervention or until the participant is ambulatory and drinking well, whichever is longer. Participants will receive standard monitoring of oxygen saturation, blood pressure, respiratory rate, apnea, heart rate, and rash by the attending nurse and physician every 5 minutes as per the usual standard of care. The usual standard of care also includes monitoring post-anesthetic for the presence of known idiosyncratic effects of ketamine that include vomiting, seizure, headache, emergence reaction, and hypersensitivity. The RA will obtain this information from the nursing record at discharge. Immediately prior to discharge, the RA will also record the duration of stay in the ED and parental satisfaction with PCS. 1. Chiaretti et al. 2011. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child. 96;160-163

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone Fractures

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intranasal ketamine and saline
Arm Type
Experimental
Arm Description
Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
Arm Title
Intravenous ketamine and saline
Arm Type
Active Comparator
Arm Description
Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
Intervention Type
Drug
Intervention Name(s)
Ketamine and saline
Other Intervention Name(s)
Ketamine hydrochloride
Intervention Description
Ketamine intravenous and intranasal
Primary Outcome Measure Information:
Title
University of Michigan Sedation Score
Description
The primary outcome is the UMSS score at 10 minutes post administration of the IV intervention compared to UMSS score immediately prior to the first IN intervention (delta) using the University of Michigan Sedation Scale (UMSS)
Time Frame
From the time the IV intervention is given to 60 minutes post intervention or when drinking, whichever is longer
Secondary Outcome Measure Information:
Title
Onset of sedation
Description
Time interval from first IN spray to UMSS score of greater than 3 in minutes
Time Frame
Within 1 hour following intervention
Title
Duration of sedation
Description
Time interval from UMSS score greater than 3 to a UMSS score of 0 in minutes
Time Frame
Within 2 hours following sedation
Title
Adverse events
Description
Obtained when patient fully awake and prior to discharge from the participant, physician report and corroborated with nursing sedation record
Time Frame
Within 2 hours following sedation
Title
Length of stay
Description
Time from arrival in ED bed to discharge in minutes
Time Frame
Within 3 hours of intervention
Title
Length of stay due to sedation
Description
Time from first IN spray to discharge in minutes
Time Frame
Within 3 hours of intervention
Title
Duration of procedure
Description
Time from first IN spray to end of cast application
Time Frame
Within 3 hours of intervention
Title
Parental satisfaction
Description
Obtained immediately prior to discharge using a 5-item Likert scale; Parents not wishing to remain in proximity of child for sedation may opt out
Time Frame
Within 2 hours of sedation
Title
Child satisfaction
Description
Obtained immediately prior to discharge using a 5-item Likert scale
Time Frame
Within 2 hours of sedation
Title
Sedating physician satisfaction
Description
Obtained immediately prior to discharge using a 5-item Likert scale
Time Frame
Duration of ED visit
Title
Adjunctive sedative medication
Description
Number of doses and type of adjunctive sedative medication required
Time Frame
Duration of ED visit
Title
Analgesic medication
Description
Number of doses and type of analgesic medication required
Time Frame
Duration of ED visit
Title
Pain
Description
Child's self reported pain score using the Faces Pain Scale - Revised
Time Frame
15 minutes prior to and 2 hours post intervention
Title
Emergence Agitation
Description
Degree of emergency agitation and delirium as recorded by observer using the Paediatric Anesthesia Emergency Delirium (PAED) scale
Time Frame
Every 5 minutes for 60 minutes starting 20 minutes post IV intervention
Title
Nasal Irritation
Description
Recorded using a 5-item Likert scale anchored from 1=none to 5=very severe when child has a UMSS score of 0 and is awake and drinking
Time Frame
Within 1 hour of intervention
Title
Successful sedation
Description
Successful sedation - Based on the definition of Bhatt et al., this will be defined as no unpleasant patient recall of the procedure, no resistance or restraint required during the procedure, no permanent sedation-related complication or no sedation-related event requiring abandonment of the procedure. Defined as: no unpleasant patient recall of the procedure, no resistance or restraint required during the procedure, no permanent sedation-related complication or no sedation-related event requiring abandonment of the procedure. Defined as no unpleasant recall of procedure, no resistance or restraint, no permanent sedation related complication, no sedation-related event requiring abandonment of procedure
Time Frame
From time of first IN spray to when participant is fully awake (UMSS score of 0 for 15 minutes)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients 5-17 years (up to 80 kg) presenting to the paediatric ED who require a PCS for an acute simple orthopedic injuries who require a procedural sedation and analgesia (PSA). A "simple" injury is defined as a fracture or dislocation that: 1) Angulated with or without displacement but is not shortened) 2) Non-comminuted Exclusion Criteria: 1) Previous hypersensitivity reaction to ketamine including rash, difficulty breathing, hypotension, apnea, or laryngospasm 2) Globe rupture 3) Traumatic brain injury with intracranial hemorrhage 4) History of uncontrolled hypertension 5) Nasal bone deformity 6) Fracture reduction expected to require > 20 minutes 7) Poor English fluency 8) American Society of Anesthesiologists (ASA) class of 3 or greater 9) Previous sedation with ketamine within 24 hours of index visit 10) Known diagnosis of schizophrenia or active psychosis 11) Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naveen Poonai, MD
Organizational Affiliation
Western University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital, London Health Sciences Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A5W9
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children

We'll reach out to this number within 24 hrs